^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners

COMPANY:
Thermo Fisher Scientific

i
Other names: Corrona | Corrona, LLC | Corrona LLC | CorEvitas | CorEvitas, LLC | CorEvitas LLC | The Binding Site | Thermo Fisher Scientific | Life Technologies Corporation | Patheon | Banner Life Sciences | Banner Pharmacaps | Sobel USA | Thermo Fisher Scientific Inc. | Thermo Fisher Scientific Inc | Thermo Scientific | Life Technologies | Banner Life Sciences LLC | Banner Life Sciences, LLC
Related tests:
Evidence

News

28d
Bayer and Thermo Fisher Scientific collaborate to increase patient access to precision cancer medicines (Thermo Fisher Scientific Press Release)
"Bayer AG and Thermo Fisher Scientific Inc...announced to develop next-generation sequencing (NGS)-based companion diagnostic assays (CDx) together. These will help identify patients who may benefit from Bayer’s growing portfolio of precision cancer therapies by offering decentralized genomic testing and rapid turnaround time...The CDx will be developed using Thermo Fisher’s Oncomine Dx Express Test on the Ion Torrent Genexus Dx System, a fully integrated NGS platform that can deliver results on a patient’s tumor or liquid biopsy sample in as little as 24 hours."
Licensing / partnership
|
Oncomine™ Dx Target Test
5ms
Thermo Fisher Scientific, Pfizer Canada Grant C$300K to study NGS in colorectal cancer care (Genomeweb)
"Thermo Fisher Scientific, Pfizer Canada, and Colorectal Cancer Canada have awarded a total of C$300,000 ($221,081) to two Canadian healthcare providers to study the use of next-generation sequencing-based testing in colorectal cancer care."
Grant
6ms
Thermo Fisher Scientific Signs Companion Diagnostic Agreement with Boehringer Ingelheim to Select Patients with NSCLC for Targeted Therapy Treatment (Businesswire)
"To support emerging precision therapies and improve patient outcomes by increasing access to reliable genomic testing needed to match patients with targeted cancer treatments, Thermo Fisher Scientific today announced a companion diagnostic (CDx) partnership with Boehringer Ingelheim. Through this collaboration, the companies will work to develop CDx tests to help identify patients with non-small cell lung cancer (NSCLC) with specific genomic mutations....The collaboration will leverage the Oncomine Dx Express Test on the Ion Torrent Genexus Dx System as well as the Oncomine Dx Target Test."
Licensing / partnership
|
Oncomine Dx Express Test
7ms
Devyser and Thermo Fisher Scientific collaborate to promote laboratory services to advance pharmaceutical research (Genomeweb)
"Swedish molecular diagnostics firm Devyser Diagnostics said on Wednesday that it has entered an agreement with Thermo Fisher Scientific to promote its laboratory services to pharmaceutical companies."
Licensing / partnership
11ms
Thermo Fisher Scientific & Pfizer partner to expand localized access to next-generation sequencing-based testing for cancer patients in international markets (Thermo Fisher Scientific Press Release)
"Pfizer and Thermo Fisher Scientific Inc...announced they have entered into a collaboration agreement to help increase local access to next-generation sequencing (NGS)-based testing for lung and breast cancer patients in more than 30 countries across Latin America, Africa, the Middle East and Asia where advanced genomic testing has previously been limited or unavailable. Access to local NGS testing can help to provide faster analysis of associated genes, empowering healthcare providers to select the right therapy for that individual patient."
Licensing / partnership
1year
Thermo Fisher Scientific Partners with AstraZeneca to Develop Solid Tissue and Blood-Based Companion Diagnostic Test for Tagrisso (Thermo Fisher Scientific Press Release)
"As part of a global, multiyear agreement, Thermo Fisher Scientific today announced it is working with AstraZeneca to develop a solid tissue and blood-based companion diagnostic (CDx) test for Tagrisso (osimertinib). The CDx will help identify patients with non-small cell lung cancer (NSCLC) who may be eligible for treatment with Tagrisso by identifying tumors that exhibit epidermal growth factor receptor (EGFR) alterations including exon 21 L858R mutations, exon 19 deletions or T790M mutations. The collaboration will leverage the Oncomine Dx Express Test on the Genexus Dx System, a fully-integrated next-generation sequencing (NGS) platform featuring an automated specimen-to-report workflow that economically delivers results in as little as 24 hours to bring test results to clinicians and patients faster."
Licensing / partnership
|
Oncomine Dx Express Test
|
Tagrisso (osimertinib)
over1year
Thermo Fisher Scientific Completes Acquisition of The Binding Site Group (Thermo Fisher Scientific Press Release)
"Thermo Fisher Scientific Inc....announced that it has completed its acquisition of The Binding Site Group ('The Binding Site'), a global leader in specialty diagnostics, from a shareholder group led by European private equity firm Nordic Capital, in an all-cash transaction valued at £2.3 billion, or $2.8 billion at current exchange rates....'The Binding Site expands our existing specialty diagnostics portfolio with the addition of pioneering innovation in diagnostics and monitoring for multiple myeloma. Early diagnosis and well-informed treatment decisions can make a significant difference in patient outcomes, and we are excited by the opportunity to enable further advancements in this area for the benefit of patients'...The transaction is expected to be accretive to adjusted earnings per share by $0.07 in 2023."
M&A
over1year
FDA Grants De Novo Classification to HLA Typing Test for Use as a Companion Diagnostic with a T Cell Receptor Therapy for Metastatic or Unresectable Uveal Melanoma (Thermo Fisher Scientific Press Release)
"Thermo Fisher Scientific Inc...announced that its SeCore CDx HLA Sequencing System was granted De Novo Classification by the United States Food and Drug Administration (FDA) for use as a companion diagnostic with KIMMTRAK® (tebentafusp-tebn), Immunocore’s T cell receptor therapy for HLA-A*02:01-positive adults with metastatic or unresectable uveal melanoma—a rare but deadly cancer of the eye. The marketing authorization is the first of its kind, making the SeCore CDx HLA Sequencing System the only commercially available HLA typing companion diagnostic....The SeCore CDx HLA Sequencing System was used to identify HLA-A*02:01 positive patients for enrollment in KIMMTRAK clinical trials."
FDA event
|
SeCore CDx HLA Sequencing System
|
Kimmtrak (tebentafusp-tebn)
over1year
Thermo Fisher Scientific to showcase new innovative laboratory solutions at AMP 2022 (Thermo Fisher Scientific Press Release)
"Thermo Fisher Scientific...is showcasing its latest innovative research and diagnostic technologies at the 2022 annual meeting and expo of the Association for Molecular Pathology (AMP) taking place at the Phoenix Convention Center from Nov. 1-5. The solutions on display are designed to address a broad range of disease states and include assays and instruments that leverage real-time and digital PCR, as well as next generation sequencing (NGS) platforms."
Clinical
over1year
Thermo Fisher Scientific Announces FDA Approval of Oncomine Dx Target Test as the First NGS-Based Companion Diagnostic to Aid in Therapy Selection for Patients with RET Mutations/Fusions in Thyroid Cancers (Thermo Fisher Scientific Press Release)
"The U.S. Food and Drug Administration (FDA) has granted approval to Thermo Fisher Scientific’s Oncomine Dx Target Test as a companion diagnostic (CDx) to aid in selection of patients with RET-fusion positive locally advanced or metastatic non-small cell lung cancer (NSCLC), RET-fusion positive advanced or metastatic thyroid cancer and RET-mutation positive advanced or metastatic medullary thyroid cancer (MTC) who may be eligible for treatment with Lilly’s Retevmo (selpercatinib)."
FDA event
|
Oncomine™ Dx Target Test
|
Retevmo (selpercatinib)
over1year
FDA approves selpercatinib for locally advanced or metastatic RET fusion-positive non-small cell lung cancer (FDA)
"On September 21, 2022, the Food and Drug Administration granted regular approval to selpercatinib (Retevmo, Eli Lilly and Company) for adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with a rearranged during transfection (RET) gene fusion, as detected by an FDA-approved test...FDA also approved the Oncomine Dx Target (ODxT) Test (Thermo Fisher Scientific) as a companion diagnostic for selpercatinib."
FDA event
|
Oncomine™ Dx Target Test
over1year
FDA grants accelerated approval to fam-trastuzumab deruxtecan-nxki for HER2-mutant non-small cell lung cancer (FDA)
"Food and Drug Administration granted accelerated approval to fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo, Inc.) for adult patients with unresectable or metastatic non-small cell lung cancer (NSCLC)...FDA also approved the Life Technologies Corporation’s Oncomine™ Dx Target Test (tissue) and the Guardant Health, Inc.’s Guardant360® CDx (plasma) as companion diagnostics for Enhertu."
FDA event
|
Guardant360® CDx • Oncomine™ Dx Target Test
over1year
Thermo Fisher Scientific introduces highly sensitive research assays for measurable residual disease detection in myeloid malignancies (Thermo Fisher Scientific Press Release)
"Thermo Fisher Scientific...launched a next-generation sequencing (NGS)-based assay for research in myeloid measurable residual disease (MRD). As the first NGS-based tests to support both DNA and RNA input, the Ion Torrent Oncomine Myeloid MRD Assays (RUO) provide a comprehensive and highly sensitive MRD assessment from blood and bone marrow samples."
Launch
|
Oncomine™ Myeloid MRD Assays
2years
Thermo Fisher Scientific calls for grant proposals to support research in cancer molecular profiling (Businesswire)
"As part of its ongoing commitment to support clinical oncology research, Thermo Fisher Scientific is calling for new proposals for its Oncomine Clinical Research Grant. The latest request for submissions from the global scientific community will award funding for molecular profiling research that helps accelerate the use of genomic sequencing in oncology...'The Oncomine Clinical Research Grant program aims to fund research furthering our understanding of cancer at the genomic level. The identification of specific cancer biomarkers associated with response or resistance to treatment can inform clinical care and potentially help predict patient outcomes'..."
Grant
2years
Oncocyte announces development and co-marketing agreement with Thermo Fisher Scientific to expand access to precision oncology (Oncocyte Press Release)
"Oncocyte Corporation...announced a development and co-marketing agreement for two distributed in vitro diagnostic (IVD) assays on Thermo Fisher Scientific’s Ion Torrent™ Genexus™ System...Under the terms of the collaboration, Oncocyte will clinically validate Thermo Fisher’s existing Oncomine Comprehensive Assay Plus* on the Genexus System, paving the way toward IVD clearance for use in tumor profiling and future submissions as a companion diagnostic...Oncocyte will also develop its 27-gene expression DetermaIO™ test as a distributed kit on the Genexus."
Licensing / partnership
|
Oncomine™ Comprehensive Assay v3M • DetermaIO™ • Oncomine™ Comprehensive Assay Plus
over2years
NeoGenomics to leverage Thermo Fisher Scientific’s Ion Torrent Genexus System in upcoming phase 1 study for myeloid cancers (NeoGenomics Press Release)
"NeoGenomics, Inc...announced it will use Thermo Fisher Scientific's Ion Torrent Genexus System, the first turnkey next-generation sequencing (NGS) solution that automates the specimen-to-report workflow to deliver results in as little as a single day, in a pharma-sponsored Phase 1 study...As part of the preclinical research investigation, NeoGenomics will receive early access to Thermo Fisher's new Oncomine Myeloid Assay GX v2 to validate the assay on the Genexus System."
New P1 trial
|
Oncomine Myeloid Assay GX
over2years
FDA Approves NGS-Based Companion Diagnostic for EGFR Exon20 Insertion Mutant Non-Small Cell Lung Cancer Tumor Tissue (Thermo Fisher Scientific Press Release)
"The U.S. Food and Drug Administration (FDA) has granted premarket approval to Thermo Fisher Scientific's Oncomine Dx Target Test as a companion diagnostic (CDx) to help identify non-small cell lung cancer (NSCLC) patients whose tumors carry epidermal growth factor receptor (EGFR) Exon20-insertion mutations for potential treatment with RYBREVANT® (amivantamab-vmjw)*, Janssen Biotech, Inc.'s (Janssen's) targeted therapy."
FDA event
|
Oncomine™ Dx Target Test
|
Rybrevant (amivantamab-vmjw)